|Systematic (IUPAC) name|
|Trade names||Myrbetriq (US), Betanis (Japan), Betmiga (EU)|
|Licence data||EMA: , US FDA:|
|Metabolism||Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase|
|Biological half-life||50 hours|
|Excretion||Urine (55%), faeces (34%)|
|CAS Registry Number|
|Molecular mass||396.506 g/mol|
Mirabegron (formerly YM-178, trade name Myrbetriq, Betmiga in Spain) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Its primary use is in the treatment of overactive bladder. Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation. 
Very common (>10% incidence) adverse effects include:
- Elevated blood pressure
Common (1-10% incidence) adverse effects include:
- Xerostomia (dry mouth)
- Urinary tract infection (UTI)
- Back pain
- Upper respiratory tract infection (URTI)
- Tachycardia (high heart rate)
- Abdominal pain
- Neoplasms (cancers)
Rare (<1% incidence) adverse effects include:
- Blurred vision
- Dyspepsia (indigestion)
- Abdominal distension
- Elevations in liver enzymes (GGT, AST, ALT & LDH)
- Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
- Reproductive system disorders (e.g., vulvovaginal pruritis, vaginal infection)
- Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
- Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin
- Urinary retention
- "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
- Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998) 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
- Sacco E, Bientinesi R, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014 Apr;9(4):433-48. doi: 10.1517/17460441.2014.892923. Epub 2014 Feb 22.PMID 2455903
- "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)". ChEMBL. 5 July 2012. Retrieved 28 September 2012.
- "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013.
- "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013.
- Cypess, Aaron; Weiner, Lauren; Roberts-Toler, Carla; Elía, Elisa; Kessler, Skyler; Kahn, Peter; English, Jeffrey; Chatman, Kelly; Trauger, Sunia; Doria, Alessandro; Kolodny, Gerald (6 January 2015). "Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist". Cell Metabolism 21 (1): 33–38. doi:10.1016/j.cmet.2014.12.009. PMID 25565203. Retrieved 26 January 2015.
- Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.